ADARx Pharmaceuticals, Inc. ADRX
13.74 USD +0.17 (+1.25%)
Nov 11, 2026, 9:49 AM EST
13.48 Day range 14.07
12.50 52-week range 23.21
- YTD
- -28.99%
- 1 year
- -28.99%
News
globenewswire.com ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, today announced…
benzinga.com JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38 JP Morgan analyst Tessa Romero initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $38.
benzinga.com This Restaurant Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated bullish coverage on ADRX ($32), NWSA ($35), MOD ($275), SITM ($750) and QSR ($85), with Overweight, Outperform or Buy ratings.
benzinga.com UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35 UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.
benzinga.com Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32 Morgan Stanley analyst Michael Ulz initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $32.